Latest News by Industry
DUBLIN--(BUSINESS WIRE)--Nov 21, 2022--
The "Hemoglobinopathies Market By Type, By Therapy, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
According to this report the hemoglobinopathies market was valued at $4.2 billion in 2021, and is estimated to reach $7 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031.
Hemoglobinopathy is a collective term used for the blood disorder that primarily affects the red blood cells (RBCs). The abnormal production or structural change in the hemoglobin molecule causes hemoglobinopathies. Majorly, hemoglobinopathies are divided into two groups, namely abnormal structural hemoglobin variant and thalassemia.
The abnormal structural hemoglobin variants are caused by mutations in the hemoglobin gene structure and thalassemia is occurred by abnormal or underproduction of hemoglobin molecules. Many hemoglobinopathies currently have some approved drugs in the market and some drugs are in development stages.
The increasing prevalence of sickle cell disease (SCD) and thalassemia is expected to drive the market growth. The key driver for the growth of the global hemoglobinopathies market is increasing prevalence of hemoglobinopathies in under-developed and developing countries. In addition, the lack of awareness and low diagnosis rate are some major factors increasing the prevalence of the hemoglobinopathies.
Moreover, the lack of treatment alternatives, unavailability of treatments and low diagnosis rate are the factors restraining the growth of the global hemoglobinopathies market during the forecast period. The hemoglobinopathies market is projected to grow with the arrival of treatments for beta thalassemia and sickle cell diseases.
Treatments based on transfer of genetically corrected stem cells, in which the lentiviral vectors transfer beta globin chain, and the transcription is regulated by the beta globin locus. For instance, there are various factors limiting growth of the market, such as insufficient stem-cell quantity and quality, gene expression complexity, and high cost of the treatment.
Key Benefits
Key Market Segments
By Type
By Therapy
By Distribution Channel
By Region
Key Market Players
For more information about this report visit https://www.researchandmarkets.com/r/pec7dw
View source version on businesswire.com:https://www.businesswire.com/news/home/20221121005352/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 11/21/2022 05:04 AM/DISC: 11/21/2022 05:04 AM
http://www.businesswire.com/news/home/20221121005352/en